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C-H-ras proto-oncogene forms part of the signal
transduction pathway of numerous external stimuli. This
proto-oncogene is regulated by alternative splicing within
its intron D due to the presence of the alternative intron D
exon (IDX). The alternative splicing produces mRNA
which encodes for the putative p19 protein, that lacks
transforming potential. Herein, we demonstrated that SR
proteins regulate the intron D splicing. Moreover, we
studied the 2719 mutation of H-ras which has higher
transforming potential than Ile12 and Val12 H-ras
mutants and is also known to affect the 5’ splice site of
the IDX. However, here we show that the 2719 mutant can
still be spliced when the upstream 5’ splice-site is blocked.
During these later studies, additionally, we generated a
short 11 nucleotides 5’ terminal exon that was fully defined
and spliced in a bi-intronic pre-mRNA. The definition of
this mini-exon was also addressed in this work.
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Alternative splicing of the c-H-ras gene is an important
regulator of p21 mRNA. The presence of the
alternative exon (IDX) between exon (E) 3 and E4A
allows for the production of a second mRNA (see
Figure 1) that encodes for the putative p19 protein,
which lacks transforming potential (Cohen et al., 1989)
and could act as a negative regulator of the p21 protein
(Huang and Cohen, 1997). IDX was discovered when
the Adenosine2719Guanosine mutant was isolated
from a carcinoma cell line as having a higher
transforming potential than codon 12 mutants (Cohen
et al., 1989; Cohen and Levinson, 1988). As the
Adenosine2719Guanosine mutant lowered the strength
(Cohen et al., 1989) of the IDX 5’ splice site (5’SS), the
study of this mutant could be of help in providing
answers as to how the IDX 5’ SS is regulated.
Therefore, we used human nuclear extracts to splice
pre-mRNAs containing only this critical E3-D intron-
E4A region to gain an indication of the level of
alternative splicing – see Figure 1a, lane 2, and Codony
et al. (2001). These experiments yielded more p21 than
p19 products (see Figure 1a, lane 2); thus indicating
that in vitro the p21 pathway is favoured in these mini-
genes. Stepwise changes in SR proteins have been
reported during mammary carcinogenesis (Stickeler et
al., 1999); we then studied whether SR proteins could
modulate this alternative splicing. We complemented
splicing reactions with a pool of purified and native SR
proteins (Figure 1a) showing that their balance and
amount could favour the p19 mRNA pathway (lanes 4
and 5). High amounts of added SR proteins could
completely inhibit the p21 pathway while still allowing
the p19 pathway to proceed (compare lanes 3 – 6 of
Figure 1a). This result would agree with the one
reported by (Mayeda et al., 1993), showing that excess
of the ASF/SF2 leads to internal exon inclusion,
although we have not observed that this splicing
pathway is regulated by ASF/SF2 (S Guil, unpublished
results). The D2 intron 5’ SS was further characterized
by assaying the Adenosine2719Guanosine H-ras
mutant. The Adenosine2719Guanosine mutation is
localized on the fourth base of the D2 intron (position
2719 of the c-H-ras gene), where a wild-type (wt)
adenosine was changed to a guanosine. As expected,
and according to the exon definition model of splicing,
the D2 intron splicing did not occur in vitro when the
mutant Adenosine2719Guanosine E3-D intron-E4A
pre-mRNA was assayed (see Figure 1b, lane 3, and
compare with lane 2, note the two p19 splicing
products). Then, we mutated the E3 to a non-related
11-nt mini-exon (see Figure 2 legend). Surprisingly, this
mutated pre-mRNA is still active in splicing reactions
(see Figure 2a lanes 2 and 3), and we conclude that
even when E3 is mutated to a very small exon (E11nt)
the splicing of intron A still proceeds. Moreover, the
substitution of the E3 by the E11nt resulted in intron B
(D2) being spliced more eciently in E11nt pre-mRNA
than in the previous E3-D intron-E4A pre-mRNA
(compare p19 products in Figure 1a, b, lanes 2, with
product B (PB) in Figure 2a, lanes 2 and 3), indicating
that the modifications favoured the alternative splicing
of the D2 intron. To know how dependent the B intron
splicing is on the two alternative 5’ SS, we mutated the
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5’ SS of the intron A. The N2=T of the intron A 5’ SS
was changed to N2=G (X in Figure 2). Figure 2a
shows that this mutation drastically reduced the
splicing of the A products (notice the presence of a
very low amount of the lariat A in lanes 5 and 6 in
Figure 2a). When the Adenosine2719Guanosine also
contained the second mutation N2=G at intron A 5’
SS, it did not render products A (lanes 11 and 12),
however now PB is obtained – notice the lariat B and
PB in lanes 11 and 12 in Figure 2a and observe that
these products are not so evident in lanes 8 and 9 in
Figure 2a. When the intron A 5’ SS is not mutated,
E4A splices more eciently with the distal exon (either
the wt E3 or the mutated E11nt), rather than with the
proximal IDX in Adenosine2719Guanosine mutant.
Whereas, when the intron A 5’ SS is mutated, D2
intron splicing could take place in Adenosine2719Gua-
nosine mutant.
The fact that a 5’ terminal mini-exon is fully active in
the splicing reaction, led us to study the definition of
this E11nt exon, since, to our knowledge, this was the
first time that such a short cap-terminal 5’ exon had
been seen to be spliced in competition with a cap-distal
5’ exon. It has already been reported that CBC, cap
structure and U1snRNA play an important role in cap-
proximal exon definition (for a review see Lewis and
Izaurralde, 1997). We therefore tested if the cap-
proximal exon of the E11nt pre-mRNA also requires
these factors. First, the effects of the 5’ SS mutation on
intron A (see lanes 5 and 6 and lanes 11 and 12 in
Figure 2a) already demonstrated that the disruption of
the U1snRNA base-pairing with the cap-proximal 5’
SS did not allow for correct E11nt definition. As
expected, GpppG- and m7GpppG-capped E11nt were
well defined – see products A lanes 3 – 6 in Figure 2b –
and as expected less of the PA was produced when the
pre-mRNAs were m3GpppG and ApppG capped (see
absence of the same products in lanes 7 – 10 in Figure
2b). This indicates that cap-structure and CBC
participates in this E11nt exon definition. It was
interesting to observe that not only is splicing of the
intron A affected in m3GpppG- and ApppG-capped
pre-mRNAs, but there is also a remarkable inhibition
of the products from cap-distal splicing B (compare
products B in lanes 3 – 6 with lanes 7 – 10 in Figure 2b,
and compare lane 2 with lanes 4 and 9 in Figure 2c).
Previously, it was demonstrated that SR proteins may
rescue splicing activity in depleted extracts – as U1-,
U2AF- or CBC-depleted extracts – (see Crispino et al.,
1994; Lewis et al., 1996; MacMillan et al., 1997; Tarn
and Steitz, 1994). We studied whether SR proteins may
rescue splicing of the m3GpppG- and ApppG-capped
E11nt pre-mRNA. Figure 2c shows that splicing of the
cap-distal intron B is clearly activated by the presence
of increasing amounts of SR proteins (see PB in lanes
4 – 7 and lanes 9 – 12 in Figure 2c), while the cap-
proximal intron A splicing is rescued to a lesser extent
(see products A in lanes 4 – 7 and lanes 9 – 12 in Figure
Figure 1 Effect of the SR proteins on the alternative splicing of intron D. (a) Splicing reactions were complemented with a pool of
native and purified SR proteins. In all figures (7) ATP indicates splicing reaction with no added ATP, other lanes show splicing
reactions with ATP. Molecular weight markers are shown either on the lane M or on the left of the figures. Lane 2 did not contain
SR proteins. SR proteins added in lanes: 3, 90 ng; 4, 180 ng; 5, 360 ng and 6, 720 ng. (b) Lane 1 and 2 contain the wild-type (wt)
sequence (with N4=A of the D2 intron 5’ SS, position 2719 of the c-H-ras gene), and lane 3 contains Adenosine2719Guanosine
mutant (with N4=G on the D2 intron 5’ SS). Lariat intermediates and products where mapped by RT–PCR as detailed elsewhere
(Vogel et al., 1997). The splicing reactions assays, E3-D intron-E4A probe, RNA sequencing and RNA gels were described else-
where (Codony et al., 2001). Similarly, Adenosine2719Guanosine mutant was obtained from ile12N(G) plasmid (Cohen et al.,
1989). Total SR proteins were purified according to the technique described in Zahler et al. (1992)
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2c). The above observations showing that there is also
an inhibition of the cap-distal splicing B with
m3GpppG- and ApppG-capped pre-mRNAs, lead us
to investigate if CBC also affects splicing B. Splicing of
E11nt pre-mRNA in CBC-depleted extracts (DCBC)
showed a clear inhibition of the cap-proximal intron
A– see products A in Figure 3a, and compare lane 3
with lane 4; but there is less inhibition of the cap-distal
intron B and therefore products B are clearly obtained
(Figure 3a). The addition of rCBC (CBP80 plus
CBP20) recovers the cap-proximal product A (compare
lane 6 with lanes 7 and 8 of Figure 3), but there is not
a significant increase of the cap-distal product B. This
result led us to conclude that only the presence of cap
structural analogs alter the E11nt pre-mRNA in such a
way that the sequence E11nt to 3’ end of IDX is
recognized as an entire 5’ terminal exon unit; however,
either by SRs rescue assays or by CBC depletion/
complementation assays, E11nt pre-mRNA behaves as
bi-intronic. This allows us to conclude that CBC
depletion renders different results when compared to
the presence of cap analogues.
Figure 2 Splicing of the mini-gene E11nt pre-mRNA containing wt and Adenosine2719Guanosine mutation on the D2 intron 5’
SS. For, E11nt plasmids, we first deleted E3 and cut the furthermost 5’ terminal 24-nt portion of the D1 intron, and ligated it into
the Bluescript SK (7) polylinker region previously cut with Acc65I. Thus, the final transcribed pre-mRNA contained the 5’ terminal
sequence GGGCGAATTGG/GTACCTAGCC (the D2 intron sequence is in bold and the added Bluescript SK (7) plasmid sequence
is in italics). The newly created 5’ SS (similar to the consensus YRG/GTRAGT) is underlined. We called this assay ‘A’ for the
(D5’)D intron splicing (cap-proximal) and ‘B’ for the D2 splicing (cap-distal); splicing products follow the same nomenclature: lariat
A/B or PA/PB (see diagram in the upper part of Figure 2). In some gels the PA was barely detected and we therefore followed the
splicing reaction by monitoring the lariat A product. (a) The plasmid containing the E11nt pre-mRNA was mutated at the E11nt 5’
SS by a PCR punctual protocol (Deng and Nickoloff, 1992; Zhu, 1996) with the two mutated oligodeoxynucleotides mutN2=G:
GGC GAA TTG GGG ACC TAG CCA GGG; and complemmutN2=G: CCC TGG CTA GGT CCC CAA TTC GCC. The
(N2=T), ‘(wt)’, in lanes 1 – 3 and 7 – 9, was changed to (N2=G), ‘X’, in lanes 4 – 6 and 10 – 12. Together with this mutation on
the E11nt 5’ SS, we also tested the Adenosine2719Guanosine H-ras mutant. N4=A is the wt pre-mRNA (in lanes 1 – 6) and
N4=G is the mutant pre-mRNA (lanes 7 – 12). Each splicing reaction was performed twice (lanes 2 and 3, 5 and 6, 8 and 9,
and 11 and 12) to better evaluate the level of product production. (b) E11nt pre-mRNA capped with the caps stated in the figure
were spliced in two independent experiments (two lanes with each cap). (c) Shows the splicing rescue of the E11nt pre-mRNA
(capped with m3GpppG and ApppG) by addition of SR proteins. Amount of SRs in 25 ml: lanes 5 and 10, 30 ng; lanes 6 and
11, 60 ng; lanes 7 and 12, 120 ng
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Our main conclusion in regard to H-ras alternative
splicing is that SR proteins could push this towards the
p19 mRNA pathway which lacks transforming poten-
tial. Interestingly, although the Adenosine2719
Guanosine mutant contains a 5’ SS mutation, it can
still be spliced when the upstream 5’ SS is mutated.
This led us to conclude that the IDX 5’ SS (even when
mutated) undergoes a splicing reaction when the
upstream 5’ SS is blocked. Hence, any specific blocking
agent of the E3 5’ SS will not only block D intron
splicing but also stimulate D2 intron splicing. It is
interesting to observe that as few as 11 nts provide
adequate room for the CBC and U1snRNA interaction
and definition of the 11-nt 5’ SS. Another aspect is that
although the distance between the cap and the distal
IDX 5’SS is short (163 nts), but equal to the size of an
average mammalian exon, CBC depletion did not
drastically affect the splicing of the cap-distal intron
B. Thus, depletion/complementation of rCBC did not
inhibit/stimulate splicing of cap-distal intron B, as it
does with the cap-proximal intron A. Therefore, the
splicing of cap-distal intron B does not depend on
CBC. This result agrees with a previous report (Lewis
et al., 1996), in which the authors showed that the
presence of a downstream 3’ SS – that is, of a
downstream polypyrimidine track (PyT) – appears to
make the cap-distal intron B independent of CBC. This
observation indicates that CBC could not interact with
the cap-distal U1snRNP, probably because this
U1snRNP is not free due to its interactions with the
3’ SS complex across the IDX. Our results allowed us
to distinguish between the CBC requirement and cap
structure. It has been previously reported that cap
structure only affects the cap-proximal intron in a bi-
intronic pre-mRNA, for a review see (Lewis and
Izaurralde, 1997). As expected, the cap structure in
our bi-intronic pre-mRNA affects the cap-proximal
intron A splicing, but surprisingly it also affects the
distal intron B splicing (see lanes 7 – 10 in Figure 2b).
This phenomenon is not clearly understood but we
suggest that when CBC is present, cap and downstream
polypyrimidine tracks are well recognized and the pre-
mRNA behaves as if bi-intronic. If CBC is depleted,
factors still binding to the 5’ SS of the cap-proximal
exon may still recognise the m7GpppG cap and the
downstream PyT, and although they cannot correctly
define the 5’ terminal exon to be spliced, the pre-
mRNA still behaves as if bi-intronic. When the cap
structure is changed to m3GpppG or ApppG, either
CBC or factors binding to the 5’ SS recognise neither
the cap nor the downstream PyT. Therefore, the pre-
mRNA behaves as monointronic, with E11nt to the 3’
end of IDX being recognized as one exon unit, and SR
proteins only rescue cap-distal splicing of m3GpppG
and ApppG capped pre-mRNAs, in accordance with
their action on any monointronic pre-mRNA. This
specific SR rescue is a novel observation which has not
been published in the literature until now.
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